Axsome Therapeutics (AXSM) Total Debt (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Total Debt data on file, last reported at $129.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Debt fell 32.1% year-over-year to $129.0 million; the trailing twelve-month figure through Mar 2026 stood at $129.0 million (down 32.1% YoY), and the FY2025 full-year result was $127.8 million, down 29.3% from the prior year.
• Total Debt advanced to $129.0 million in Q1 2026, from $127.8 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $190.0 million in Q1 2025 to a low of $49.3 million in Q1 2022.
• A 5-year average of $141.0 million and a median of $129.0 million in 2026 frame the typical range for Total Debt.
• Across the five-year window, Total Debt jumped 211.51% in 2023 and slumped 52.13% in 2024, its largest moves.
• Tracing AXSM's Total Debt over 5 years: stood at $100.2 million in 2022, then jumped by 84.18% to $184.5 million in 2023, then decreased by 2.04% to $180.7 million in 2024, then slipped by 29.3% to $127.8 million in 2025, then grew by 0.97% to $129.0 million in 2026.
• Business Quant data shows AXSM's Total Debt at $129.0 million in Q1 2026, $127.8 million in Q4 2025, and $127.3 million in Q3 2025.